Literature DB >> 18981217

Lysine-independent turnover of cyclin G1 can be stabilized by B'alpha subunits of protein phosphatase 2A.

Hongyun Li1, Koji Okamoto, Melissa J Peart, Carol Prives.   

Abstract

Although the cyclin G1 gene is known to be regulated at the transcriptional level by p53, less is understood about the turnover of its protein product. We found that ectopically and endogenously expressed cyclin G1 protein is highly unstable and is degraded by a proteasome-mediated pathway. The N-terminal 137 amino acids of cyclin G1 (cyclin G(1-137)) are necessary and sufficient for both cyclin G1 ubiquitination and turnover. Interestingly, a mutant cyclin G1 (8KR) in which all lysine residues in this region have been replaced with arginine can be both ubiquitinated in cells and stabilized by a proteasome inhibitor to a similar extent as wild-type cyclin G(1-137). Furthermore, the presence of a six-Myc tag at the N terminus of cyclin G(1-137) significantly inhibits the protein's turnover, suggesting a role for the extreme N terminus of the protein in ubiquitin-mediated proteolysis. Although we and others previously showed that cyclin G1 protein can bind to MDM2, which functions as an E3 ubiquitin ligase to p53 and itself, cyclin G1 protein can be degraded in cells without MDM2 and p53. Interestingly, the B'alpha1 subunit of the serine/threonine protein phosphatase 2A, which binds to cyclin G1, can stabilize cyclin G1 under unstressed conditions and upon DNA damage, as well as inhibit the ability of cyclin G1 to be ubiquitinated. Our results thus indicate that proteasomal turnover of cyclin G1 is regulated by noncanonical processes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18981217      PMCID: PMC2630686          DOI: 10.1128/MCB.00907-08

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  63 in total

1.  A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells.

Authors:  Elizabeth Yeh; Melissa Cunningham; Hugh Arnold; Dawn Chasse; Teresa Monteith; Giovanni Ivaldi; William C Hahn; P Todd Stukenberg; Shirish Shenolikar; Takafumi Uchida; Christopher M Counter; Joseph R Nevins; Anthony R Means; Rosalie Sears
Journal:  Nat Cell Biol       Date:  2004-03-14       Impact factor: 28.824

2.  Characterisation of human cyclin G1 and G2: DNA damage inducible genes.

Authors:  S Bates; S Rowan; K H Vousden
Journal:  Oncogene       Date:  1996-09-05       Impact factor: 9.867

3.  Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53.

Authors:  R Montes de Oca Luna; D S Wagner; G Lozano
Journal:  Nature       Date:  1995-11-09       Impact factor: 49.962

4.  The tumor suppressor protein p16(INK4a) and the human papillomavirus oncoprotein-58 E7 are naturally occurring lysine-less proteins that are degraded by the ubiquitin system. Direct evidence for ubiquitination at the N-terminal residue.

Authors:  Ronen Ben-Saadon; Ifat Fajerman; Tamar Ziv; Ulf Hellman; Alan L Schwartz; Aaron Ciechanover
Journal:  J Biol Chem       Date:  2004-07-14       Impact factor: 5.157

5.  The negative role of cyclin G in ATM-dependent p53 activation.

Authors:  Takao Ohtsuka; Michael R Jensen; Hyung Gu Kim; Kyung-Tae Kim; Sam W Lee
Journal:  Oncogene       Date:  2004-07-08       Impact factor: 9.867

6.  Specific interaction between the p53 cellular tumour antigen and major heat shock proteins.

Authors:  O Pinhasi-Kimhi; D Michalovitz; A Ben-Zeev; M Oren
Journal:  Nature       Date:  1986 Mar 13-19       Impact factor: 49.962

7.  MDM2 is a negative regulator of p21WAF1/CIP1, independent of p53.

Authors:  Zhuo Zhang; Hui Wang; Mao Li; Sudhir Agrawal; Xinbin Chen; Ruiwen Zhang
Journal:  J Biol Chem       Date:  2004-02-03       Impact factor: 5.157

8.  N-terminal polyubiquitination and degradation of the Arf tumor suppressor.

Authors:  Mei-Ling Kuo; Willem den Besten; David Bertwistle; Martine F Roussel; Charles J Sherr
Journal:  Genes Dev       Date:  2004-08-01       Impact factor: 11.361

9.  Identification of a novel protein phosphatase 2A regulatory subunit highly expressed in muscle.

Authors:  M A Tehrani; M C Mumby; C Kamibayashi
Journal:  J Biol Chem       Date:  1996-03-01       Impact factor: 5.157

10.  Cyclin G is a transcriptional target of the p53 tumor suppressor protein.

Authors:  K Okamoto; D Beach
Journal:  EMBO J       Date:  1994-10-17       Impact factor: 11.598

View more
  6 in total

1.  The role of Cyclin G1 in cellular proliferation and apoptosis of human epithelial ovarian cancer.

Authors:  Lifei Jiang; Rong Liu; Yingying Wang; Chunmiao Li; Qinghua Xi; Jianxin Zhong; Jian Liu; Shuyun Yang; Juan Wang; Menghui Huang; Chunhui Tang; Zheng Fang
Journal:  J Mol Histol       Date:  2015-05-17       Impact factor: 2.611

2.  Silencing CCNG1 protects MPC-5 cells from high glucose-induced proliferation-inhibition and apoptosis-promotion via MDM2/p53 signaling pathway.

Authors:  Ye Chen; Rui Yan; Bo Li; Jun Liu; Xiaoxia Liu; Wenyu Song; Chunling Zhu
Journal:  Int Urol Nephrol       Date:  2020-02-03       Impact factor: 2.370

3.  Translational and post-translational regulation of mouse cation transport regulator homolog 1.

Authors:  Yuki Nomura; Yoko Hirata; Kazutoshi Kiuchi; Kentaro Oh-Hashi
Journal:  Sci Rep       Date:  2016-06-15       Impact factor: 4.379

4.  miR-488-3p Protects Cardiomyocytes against Doxorubicin-Induced Cardiotoxicity by Inhibiting CyclinG1.

Authors:  Mingjing Yan; Yuan Cao; Que Wang; Kun Xu; Lin Dou; Xiuqing Huang; Beidong Chen; Weiqing Tang; Ming Lan; Bing Liu; Kaiyi Zhu; Yao Yang; Shenghui Sun; Xiyue Zhang; Yong Man; Mingyan Hei; Tao Shen; Jian Li
Journal:  Oxid Med Cell Longev       Date:  2022-02-10       Impact factor: 6.543

Review 5.  Non-lysine ubiquitylation: Doing things differently.

Authors:  Ian R Kelsall
Journal:  Front Mol Biosci       Date:  2022-09-19

6.  Cell cycle checkpoint control: The cyclin G1/Mdm2/p53 axis emerges as a strategic target for broad-spectrum cancer gene therapy - A review of molecular mechanisms for oncologists.

Authors:  Erlinda M Gordon; Joshua R Ravicz; Seiya Liu; Sant P Chawla; Frederick L Hall
Journal:  Mol Clin Oncol       Date:  2018-06-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.